Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast ...

Kazia Therapeutics (KZIA) announced the sale of all intellectual property and trademarks rights to Cantrixil for $1M. In March 2021, Vivesto ...

Australian biotech Kazia Therapeutics (NASDAQ:KZIA) announced Tuesday that the U.S. FDA has indicated that data on overall survival from its GBM-AGILE study data would not be appropriate for ...

1 Day KZIA -9.45% DJIA -5.50% Russell 2K -4.37% Health Care/Life Sciences 4.56% ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...

Short interest in Kazia Therapeutics Ltd (NASDAQ:KZIA) decreased during the last reporting period, falling from 90.49K to 59.58K. This put 1.07% of the company's publicly available shares short.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced a research grant awarded from The Michael J. Fox Foundation for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...